These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32653439)

  • 1. Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS.
    Volonté C; Morello G; Spampinato AG; Amadio S; Apolloni S; D'Agata V; Cavallaro S
    Ageing Res Rev; 2020 Sep; 62():101121. PubMed ID: 32653439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis.
    Morello G; Salomone S; D'Agata V; Conforti FL; Cavallaro S
    Front Neurosci; 2020; 14():577755. PubMed ID: 33192262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.
    Fiscon G; Conte F; Amadio S; Volonté C; Paci P
    Neurotherapeutics; 2021 Jul; 18(3):1678-1691. PubMed ID: 33987813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.
    Mitropoulos K; Katsila T; Patrinos GP; Pampalakis G
    OMICS; 2018 Jan; 22(1):52-64. PubMed ID: 29356625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From use of omics to systems biology: Identifying therapeutic targets for amyotrophic lateral sclerosis.
    Castelli L; Vasta R; Allen SP; Waller R; Chiò A; Traynor BJ; Kirby J
    Int Rev Neurobiol; 2024; 176():209-268. PubMed ID: 38802176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS).
    Volonté C; Apolloni S; Sabatelli M
    Pharmacol Ther; 2019 Oct; 202():120-131. PubMed ID: 31233766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling.
    Morello G; Conforti FL; Parenti R; D'Agata V; Cavallaro S
    Curr Med Chem; 2015; 22(17):2004-21. PubMed ID: 25850769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'Omics' of Amyotrophic Lateral Sclerosis.
    Caballero-Hernandez D; Toscano MG; Cejudo-Guillen M; Garcia-Martin ML; Lopez S; Franco JM; Quintana FJ; Roodveldt C; Pozo D
    Trends Mol Med; 2016 Jan; 22(1):53-67. PubMed ID: 26691296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression.
    Zandonà A; Vasta R; Chiò A; Di Camillo B
    BMC Bioinformatics; 2019 Apr; 20(Suppl 4):118. PubMed ID: 30999865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets.
    Bosco DA; Landers JE
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):779-90. PubMed ID: 20942785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy Number Variations in Amyotrophic Lateral Sclerosis: Piecing the Mosaic Tiles Together through a Systems Biology Approach.
    Morello G; Guarnaccia M; Spampinato AG; La Cognata V; D'Agata V; Cavallaro S
    Mol Neurobiol; 2018 Feb; 55(2):1299-1322. PubMed ID: 28120152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.
    Morello G; Cavallaro S
    Future Med Chem; 2015; 7(10):1335-59. PubMed ID: 26144267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and future targets for development in amyotrophic lateral sclerosis.
    Menon P; Kiernan MC; Vucic S
    Curr Med Chem; 2014; 21(31):3535-50. PubMed ID: 24934359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
    Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
    J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.
    Apolloni S; Fabbrizio P; Parisi C; Amadio S; Volonté C
    Mol Neurobiol; 2016 Jan; 53(1):518-531. PubMed ID: 25482048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis.
    Pampalakis G; Mitropoulos K; Xiromerisiou G; Dardiotis E; Deretzi G; Anagnostouli M; Katsila T; Rentzos M; Patrinos GP
    Hum Mutat; 2019 Apr; 40(4):361-373. PubMed ID: 30556231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocytes Pathology in ALS: A Potential Therapeutic Target?
    Johann S
    Curr Pharm Des; 2017; 23(33):5022-5036. PubMed ID: 28619000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New kid on the block: does histamine get along with inflammation in amyotrophic lateral sclerosis?
    Volonté C; Parisi C; Apolloni S
    CNS Neurol Disord Drug Targets; 2015; 14(5):677-86. PubMed ID: 25714965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure.
    Beghi E; Mennini T; Bendotti C; Bigini P; Logroscino G; Chiò A; Hardiman O; Mitchell D; Swingler R; Traynor BJ; Al-Chalabi A
    Curr Med Chem; 2007; 14(30):3185-200. PubMed ID: 18220753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging targets and treatments in amyotrophic lateral sclerosis.
    Zinman L; Cudkowicz M
    Lancet Neurol; 2011 May; 10(5):481-90. PubMed ID: 21511200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.